Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OHR Pharmaceutical Inc    

OHR PHARMACEUTICAL INC

SummaryChartsNewsCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

OHR PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Ohr Pharmaceutical, Inc. - OHRP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 05:48pm EDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Ohr Pharmaceutical, Inc. (“Ohr”) (NasdaqCM: OHRP) with NeuBase Therapeutics, Inc. (“NeuBase”) in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-ohrp/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OHR PHARMACEUTICAL INC
10/18NEUBASE THERAPEUTICS : Announces Issuance of Foundational Patent Covering the Ke..
AQ
10/17NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the K..
GL
10/14NEUBASE THERAPEUTICS : Announces Appointment of Cancer Biologist and RNA Therape..
AQ
10/11NeuBase Therapeutics Announces Appointment of Cancer Biologist and RNA Therap..
GL
10/03NEUBASE THERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form..
AQ
09/26NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines C..
GL
09/09NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disea..
GL
08/14OHR : Fiscal 3Q Earnings Snapshot
AQ
08/14NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter ..
GL
08/07NeuBase Therapeutics to Ring the NASDAQ Closing Bell Today
GL
More news
Chart OHR PHARMACEUTICAL INC
Duration : Period :
OHR Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Dietrich A. Stephan Chairman & Chief Executive Officer
Samuel I. Backenroth Chief Financial Officer & SVP-Business Development
Robert Friedlander Consulting Chief Medical Officer
Danith Ly Chief Scientific Officer
Dov A. Goldstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OHR PHARMACEUTICAL INC5,190.70%90
IQVIA HOLDINGS INC.22.98%27 985
LONZA GROUP35.49%25 918
CELLTRION, INC.--.--%20 866
INCYTE CORPORATION23.46%16 885
SEATTLE GENETICS, INC.74.09%16 762